文献速递手外科与足踝外科骨质疏松与代谢性骨病

以腕管综合征为首发表现的系统性淀粉样变性诊断:指导腕管松解时活检的风险列线图

Diagnosing Systemic Amyloidosis Presenting as Carpal Tunnel Syndrome: A Risk Nomogram to Guide Biopsy at Time of Carpal Tunnel Release.
PubMed 文献 · J Bone Joint Surg Am · 2021-01-01

本研究基于美国退伍军人健康管理数据库2000至2019年89,981例接受腕管松解术且无已知淀粉样变性的成人回顾性队列,发现术后10年淀粉样变性累积发生率为0.55%(95%CI:0.47%至0.63%),中位诊断间隔4.5年。淀粉样变性诊断与心力衰竭(HR 4.68;95%CI:4.26至5.55)和死亡(HR 1.27;95%CI:1.07至1.51)风险增加相关。年龄、男性、黑人种族、单克隆丙种球蛋白病或骨髓瘤、类风湿关节炎、房颤、椎管狭窄和双侧腕管综合征为独立风险因素,并构建风险列线图以指导腕管松解时腱滑膜活检。

要点

  • 腕管松解术后10年淀粉样变性累积发生率为0.55%。
  • 术后淀粉样变性诊断与心衰和死亡风险增加独立相关。
  • 年龄、男性、黑人种族、单克隆丙种球蛋白病或骨髓瘤、类风湿关节炎、房颤、椎管狭窄和双侧腕管综合征为独立风险因素。

核心结论

  • 腕管松解术后淀粉样变性诊断虽少见,但与不良结局相关,所构建的风险列线图可指导腕管松解时腱滑膜活检。

研究设计与样本

  • 回顾性队列研究,纳入美国退伍军人健康管理数据库2000至2019年89,981例无已知淀粉样变性且接受至少1次腕管松解的成人。
  • 基于多变量竞争风险模型构建预测列线图并进行交叉验证。

主要发现

  • 89,981例接受腕管松解的患者中,310例后续诊断为淀粉样变性,中位间隔4.5年,10年累积发生率为0.55%(95%CI:0.47%至0.63%)。
  • 调整潜在混杂因素后,淀粉样变性诊断与心力衰竭风险增加相关(HR 4.68;95%CI:4.26至5.55)。
  • 调整潜在混杂因素后,淀粉样变性诊断与死亡风险增加相关(HR 1.27;95%CI:1.07至1.51)。
  • 年龄、男性、黑人种族、单克隆丙种球蛋白病或骨髓瘤、类风湿关节炎、房颤、椎管狭窄和双侧腕管综合征为独立风险因素并纳入列线图。

关键数值与推荐

  • 列线图纳入的独立风险因素:年龄、男性、黑人种族、单克隆丙种球蛋白病或骨髓瘤、类风湿关节炎、房颤、椎管狭窄、双侧腕管综合征。
  • 证据等级:预后Level IV。

临床怎么用

  • 在腕管松解术前可依据列线图评估淀粉样变性风险,以指导是否在术中行腱滑膜活检。

局限性

  • 本研究为回顾性队列研究,证据等级为预后Level IV。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: As carpal tunnel syndrome often precedes other signs of systemic amyloidosis, tenosynovial biopsy at the time of carpal tunnel release may facilitate early diagnosis and treatment. However, evidence-based guidelines for amyloidosis screening during carpal tunnel release have not been established. We sought to develop a predictive model for amyloidosis after carpal tunnel release to inform screening efforts. METHODS: We performed a retrospective cohort study of adults without known amyloidosis undergoing at least 1 carpal tunnel release from 2000 to 2019 with use of the national Veterans Health Administration database. After estimating the cumulative incidence of amyloidosis after carpal tunnel release, we identified risk factors, constructed a predictive nomogram based on a multivariable subdistribution-hazard competing-risks model, and performed cross-validation. RESULTS: Among 89,981 patients undergoing at least 1 carpal tunnel release, 310 were subsequently diagnosed with amyloidosis at a median interval of 4.5 years, corresponding to a cumulative incidence of 0.55% (95% confidence interval [CI]: 0.47% to 0.63%) at 10 years. Amyloidosis diagnosis following carpal tunnel release was associated with an increased hazard of heart failure (hazard ratio [HR], 4.68; 95% CI: 4.26 to 5.55) and death (HR, 1.27; 95% CI: 1.07 to 1.51) after adjustment for potential confounders. Age, male sex, Black race, monoclonal gammopathy of undetermined significance or multiple myeloma, rheumatoid arthritis, atrial fibrillation, spinal stenosis, and bilateral carpal tunnel syndrome were independently associated with increased risk of amyloidosis diagnosis and were included in the risk nomogram. CONCLUSIONS: Amyloidosis diagnosis after carpal tunnel release is rare but is associated with poor outcomes. We present an amyloidosis-risk nomogram to help guide tenosynovial biopsy at time of carpal tunnel release. LEVEL OF EVIDENCE: Prognostic Level IV. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Sood RF, Kamenko S, McCreary E, et al. Diagnosing Systemic Amyloidosis Presenting as Carpal Tunnel Syndrome: A Risk Nomogram to Guide Biopsy at Time of Carpal Tunnel Release. J Bone Joint Surg Am. 2021. PMID: 34097669. doi:10.2106/JBJS.20.02093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。